CARLSBAD, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed secondary public offering of 4,200,000 shares of common stock. The shares of common stock to be registered are currently owned and will be offered and sold by certain existing stockholders, who will receive all of the net proceeds from this offering. Genoptix, Inc. will not be selling any shares of its common stock and will not receive any proceeds from the sale of the shares of common stock being registered. There can be no assurance as to whether or when any such offering would commence or be completed, or as to the actual size or terms of any such offering.
The offering is being made through an underwriting syndicate led by Lehman Brothers Inc. acting as sole book-running manager. Banc of America Securities LLC and UBS Investment Bank are acting as joint lead managers with Cowen and Company, LLC as co-manager. The underwriters have a 30-day option to purchase up to 630,000 additional shares of common stock from these existing stockholders.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This offering is being made by the existing stockholders solely by means of written prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, by contacting Lehman Brothers Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, (fax): 631-254-7140, or e-mail email@example.com, or at the Securities and Exchange Commission's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from those projected. Genoptix disclaims, however, any intent or obligations to update these forward-looking statements.
|SOURCE Genoptix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved